Log In
BCIQ
Print this Print this
 

andexanet alfa (PRT064445, PRT4445)

  Manage Alerts
Collapse Summary General Information
Company Portola Pharmaceuticals Inc.
DescriptionModified human Factor Xa protein that acts as a decoy to target and sequester Factor Xa inhibitors
Molecular Target
Mechanism of ActionReverse anticoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentRegistration
Standard IndicationBleeding
Indication DetailsReverse anticoagulant activity of Factor Xa inhibitors
Regulatory Designation U.S. - Breakthrough Therapy (Reverse anticoagulant activity of Factor Xa inhibitors);
U.S. - Orphan Drug (Reverse anticoagulant activity of Factor Xa inhibitors);
U.S. - Priority Review (Reverse anticoagulant activity of Factor Xa inhibitors)
PartnerBristol-Myers Squibb Co.;
Pfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

8

$105.0M

$20.0M

$90.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today